# Clinical Trial of SARS-CoV-2 mRNA Vaccine in China

> **NCT05364047** · PHASE1 · UNKNOWN · sponsor: **AIM Vaccine Co., Ltd.** · enrollment: 144 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Low-dose of LVRNA009
- **BIOLOGICAL:** Middle-dose of LVRNA009
- **BIOLOGICAL:** High-dose of LVRNA009
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05364047
- **Lead sponsor:** AIM Vaccine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-31
- **Primary completion:** 2022-10-14
- **Final completion:** 2023-10
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2022-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05364047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05364047, "Clinical Trial of SARS-CoV-2 mRNA Vaccine in China". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05364047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*